Retinopathy Of Prematurity - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：43頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Retinopathy Of Prematurity - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Retinopathy Of Prematurity - Pipeline Review, H1 2014’, provides an overview of the Retinopathy Of Prematurity’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinopathy Of Prematurity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinopathy Of Prematurity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinopathy Of Prematurity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Retinopathy Of Prematurity - Pipeline Review, H1 2014’, provides an overview of the Retinopathy Of Prematurity’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinopathy Of Prematurity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinopathy Of Prematurity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinopathy Of Prematurity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinopathy Of Prematurity Overview 6
Therapeutics Development 7
Pipeline Products for Retinopathy Of Prematurity - Overview 7
Pipeline Products for Retinopathy Of Prematurity - Comparative Analysis 8
Retinopathy Of Prematurity - Therapeutics under Development by Companies 9
Retinopathy Of Prematurity - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Retinopathy Of Prematurity - Products under Development by Companies 13
Retinopathy Of Prematurity - Companies Involved in Therapeutics Development 14
Insmed Incorporated 14
Acucela Inc. 15
Gene Signal International SA 16
Biomar Microbial Technologies 17
Retinopathy Of Prematurity - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
mecasermin rinfabate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
aganirsen - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Drug For Retinopathy Of Prematurity - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
emixustat hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IB-09A0133 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
R-200 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Retinopathy Of Prematurity - Recent Pipeline Updates 36
Retinopathy Of Prematurity - Dormant Projects 39
Retinopathy Of Prematurity - Product Development Milestones 40
Featured News & Press Releases 40
Sep 23, 2009: Insmed And Premacure Cite Study Results Demonstrating Potential Effectiveness Of IPLEX(TM) In Preventing Blindness In Premature Infants 40
Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43
List of Tables
Number of Products under Development for Retinopathy Of Prematurity, H1 2014 7
Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Retinopathy Of Prematurity - Pipeline by Insmed Incorporated, H1 2014 14
Retinopathy Of Prematurity - Pipeline by Acucela Inc., H1 2014 15
Retinopathy Of Prematurity - Pipeline by Gene Signal International SA, H1 2014 16
Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Retinopathy Of Prematurity Therapeutics - Recent Pipeline Updates, H1 2014 36
Retinopathy Of Prematurity - Dormant Projects, H1 2014 39
List of Figures
Number of Products under Development for Retinopathy Of Prematurity, H1 2014 7
Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinopathy Of Prematurity Overview 6
Therapeutics Development 7
Pipeline Products for Retinopathy Of Prematurity - Overview 7
Pipeline Products for Retinopathy Of Prematurity - Comparative Analysis 8
Retinopathy Of Prematurity - Therapeutics under Development by Companies 9
Retinopathy Of Prematurity - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Retinopathy Of Prematurity - Products under Development by Companies 13
Retinopathy Of Prematurity - Companies Involved in Therapeutics Development 14
Insmed Incorporated 14
Acucela Inc. 15
Gene Signal International SA 16
Biomar Microbial Technologies 17
Retinopathy Of Prematurity - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
mecasermin rinfabate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
aganirsen - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Drug For Retinopathy Of Prematurity - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
emixustat hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IB-09A0133 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
R-200 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Retinopathy Of Prematurity - Recent Pipeline Updates 36
Retinopathy Of Prematurity - Dormant Projects 39
Retinopathy Of Prematurity - Product Development Milestones 40
Featured News & Press Releases 40
Sep 23, 2009: Insmed And Premacure Cite Study Results Demonstrating Potential Effectiveness Of IPLEX(TM) In Preventing Blindness In Premature Infants 40
Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43
List of Tables
Number of Products under Development for Retinopathy Of Prematurity, H1 2014 7
Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Retinopathy Of Prematurity - Pipeline by Insmed Incorporated, H1 2014 14
Retinopathy Of Prematurity - Pipeline by Acucela Inc., H1 2014 15
Retinopathy Of Prematurity - Pipeline by Gene Signal International SA, H1 2014 16
Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Retinopathy Of Prematurity Therapeutics - Recent Pipeline Updates, H1 2014 36
Retinopathy Of Prematurity - Dormant Projects, H1 2014 39
List of Figures
Number of Products under Development for Retinopathy Of Prematurity, H1 2014 7
Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
